Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):490–495. doi: 10.1038/sj.bjc.6690720

Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination

H Yu 1, M A Levesque 2,3, G M Clark 4, E P Diamandis 2,3
PMCID: PMC2362935  PMID: 10507775

Abstract

p53 gene mutation is the most common genetic alteration in neoplastic diseases, including breast cancer, for which p53 alteration may indicate poor prognosis. Recent clinical evidence suggests that prostate-specific antigen (PSA) expression may identify breast cancer patients with favourable outcome. Assessment of p53 and PSA in combination, potentially offering improved prediction, has not yet been performed. Extracts from 952 primary breast carcinomas were assayed for PSA and p53 by quantitative enzyme-linked immunosorbent assays (ELISAs) developed by the authors. Concentrations of each marker were classified as negative or positive on the basis of median and 30th percentile cut-off points for p53 and PSA respectively. Patients followed for a median of 6 years having different combinations of negative or positive status for PSA and p53 were compared with respect to the relative risks (RRs) for relapse and death by Cox proportional hazards regression analysis, in which an interaction term was also evaluated, and with respect to disease-free survival (DFS) and overall survival (OS) probabilities by Kaplan–Meier plots and log-rank tests. Multivariate models were adjusted for oestrogen and progesterone receptor status, nodal status, patient age, tumour size, DNA ploidy, S phase fraction and receipt of chemotherapy. Interactions were not found between the status of PSA and p53 in the Cox models, in which PSA-negativity (RR = 1.47, P = 0.020 for DFS, and RR = 1.49, P = 0.023 for OS) and p53-positivity (RR = 1.46, P = 0.017 for DFS, and RR = 1.41, P = 0.033 for OS) were individually associated with prognosis. Evaluation of a combined three-level variable revealed that PSA(–)/p53(+) patients had significantly higher risks for relapse (RR = 2.13, P < 0.001) and death (RR = 2.08, P = 0.001) than PSA(+)/p53(–) patients, and that patients positive or negative for both markers had intermediate risks for the outcome events in the same multivariate analysis (RR = 1.45 for both DFS and OS). The results of our study demonstrate that the assessment of combined PSA and p53 expression status by ELISAs, easily applicable to breast tumour extracts prepared for steroid hormone receptor analyses, may stratify breast cancer patients into groups differing by relapse and death risks of greater magnitude than offered by the assessment of either p53 or PSA alone. © 1999 Cancer Research Campaign

Keywords: prostate-specific antigen; protein, p53; ELISA; breast neoplasms

Full Text

The Full Text of this article is available as a PDF (83.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Elledge R., Fuqua S. A., Brown R. W., Chamness G. C., Osborne C. K., McGuire W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 3;85(3):200–206. doi: 10.1093/jnci/85.3.200. [DOI] [PubMed] [Google Scholar]
  2. Borg A., Lennerstrand J., Stenmark-Askmalm M., Fernö M., Brisfors A., Ohrvik A., Stål O., Killander D., Lane D., Brundell J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer. 1995 May;71(5):1013–1017. doi: 10.1038/bjc.1995.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B. R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995 Oct 19;377(6550):646–649. doi: 10.1038/377646a0. [DOI] [PubMed] [Google Scholar]
  4. Chang F., Syrjänen S., Tervahauta A., Syrjänen K. Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer. 1993 Oct;68(4):653–661. doi: 10.1038/bjc.1993.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  6. Clark G. M., McGuire W. L. Progesterone receptors and human breast cancer. Breast Cancer Res Treat. 1983;3(2):157–163. doi: 10.1007/BF01803558. [DOI] [PubMed] [Google Scholar]
  7. Clements J., Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994 Jun;78(6):1536–1539. doi: 10.1210/jcem.78.6.7515392. [DOI] [PubMed] [Google Scholar]
  8. Cohen P., Graves H. C., Peehl D. M., Kamarei M., Giudice L. C., Rosenfeld R. G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992 Oct;75(4):1046–1053. doi: 10.1210/jcem.75.4.1383255. [DOI] [PubMed] [Google Scholar]
  9. Cohen P., Peehl D. M., Graves H. C., Rosenfeld R. G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994 Sep;142(3):407–415. doi: 10.1677/joe.0.1420407. [DOI] [PubMed] [Google Scholar]
  10. Diamandis E. P., Levesque M. A. Assessment of p53 overexpression by non-immunohistochemical methods. J Pathol. 1995 Jan;175(1):93–95. doi: 10.1002/path.1711750114. [DOI] [PubMed] [Google Scholar]
  11. Diamandis E. P., Yu H., López-Otín C. Prostate specific antigen--a new constituent of breast cyst fluid. Breast Cancer Res Treat. 1996;38(3):259–264. doi: 10.1007/BF01806144. [DOI] [PubMed] [Google Scholar]
  12. Diamandis E. P., Yu H., Sutherland D. J. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat. 1994;32(3):301–310. doi: 10.1007/BF00666007. [DOI] [PubMed] [Google Scholar]
  13. Dressler L. G., Seamer L. C., Owens M. A., Clark G. M., McGuire W. L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer. 1988 Feb 1;61(3):420–427. doi: 10.1002/1097-0142(19880201)61:3<420::aid-cncr2820610303>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  14. Ferguson R. A., Yu H., Kalyvas M., Zammit S., Diamandis E. P. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem. 1996 May;42(5):675–684. [PubMed] [Google Scholar]
  15. Gasparini G., Pozza F., Harris A. L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst. 1993 Aug 4;85(15):1206–1219. doi: 10.1093/jnci/85.15.1206. [DOI] [PubMed] [Google Scholar]
  16. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  17. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821–1828. doi: 10.1126/science.7997877. [DOI] [PubMed] [Google Scholar]
  18. Karp J. E., Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med. 1995 Apr;1(4):309–320. doi: 10.1038/nm0495-309. [DOI] [PubMed] [Google Scholar]
  19. Lane D. P. The regulation of p53 function: Steiner Award Lecture. Int J Cancer. 1994 Jun 1;57(5):623–627. doi: 10.1002/ijc.2910570502. [DOI] [PubMed] [Google Scholar]
  20. Levesque M. A., Clark G. M., Yu H., Diamandis E. P. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer. 1995 Sep;72(3):720–727. doi: 10.1038/bjc.1995.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Levesque M. A., D'Costa M., Angelopoulou K., Diamandis E. P. Time-resolved immunofluorometric assay of p53 protein. Clin Chem. 1995 Dec;41(12 Pt 1):1720–1729. [PubMed] [Google Scholar]
  22. Levesque M. A., Yu H., Clark G. M., Diamandis E. P. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. J Clin Oncol. 1998 Aug;16(8):2641–2650. doi: 10.1200/JCO.1998.16.8.2641. [DOI] [PubMed] [Google Scholar]
  23. Levine A. J., Perry M. E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994 Mar;69(3):409–416. doi: 10.1038/bjc.1994.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lianidou E. S., Levesque M. A., Katsaros D., Angelopoulou K., Yu H., Genta F., Arisio R., Massobrio M., Bharaj B., Diamandis E. P. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Res. 1999 Jan-Feb;19(1B):749–756. [PubMed] [Google Scholar]
  25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  26. McGuire W. L., Clark G. M. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992 Jun 25;326(26):1756–1761. doi: 10.1056/NEJM199206253262607. [DOI] [PubMed] [Google Scholar]
  27. Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
  28. Partin A. W., Oesterling J. E. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994 Nov;152(5 Pt 1):1358–1368. doi: 10.1016/s0022-5347(17)32422-9. [DOI] [PubMed] [Google Scholar]
  29. Pollen J. J., Dreilinger A. Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. Urology. 1984 Mar;23(3):303–304. [PubMed] [Google Scholar]
  30. Pummer K., Wirnsberger G., Pürstner P., Stettner H., Wandschneider G. False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol. 1992 Jul;148(1):21–23. doi: 10.1016/s0022-5347(17)36497-2. [DOI] [PubMed] [Google Scholar]
  31. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  32. Thor A. D., Moore DH I. I., Edgerton S. M., Kawasaki E. S., Reihsaus E., Lynch H. T., Marcus J. N., Schwartz L., Chen L. C., Mayall B. H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992 Jun 3;84(11):845–855. doi: 10.1093/jnci/84.11.845. [DOI] [PubMed] [Google Scholar]
  33. Yu H., Diamandis E. P., Levesque M., Asa S. L., Monne M., Croce C. M. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res. 1995 Apr 15;55(8):1603–1606. [PubMed] [Google Scholar]
  34. Yu H., Diamandis E. P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C. M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171–178. doi: 10.1007/BF01806212. [DOI] [PubMed] [Google Scholar]
  35. Yu H., Diamandis E. P. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem. 1995 Feb;41(2):204–210. [PubMed] [Google Scholar]
  36. Yu H., Diamandis E. P. Prostate-specific antigen in milk of lactating women. Clin Chem. 1995 Jan;41(1):54–58. [PubMed] [Google Scholar]
  37. Yu H., Diamandis E. P., Sutherland D. J. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem. 1994 Apr;27(2):75–79. doi: 10.1016/0009-9120(94)90015-9. [DOI] [PubMed] [Google Scholar]
  38. Yu H., Diamandis E. P., Zarghami N., Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat. 1994;32(3):291–300. doi: 10.1007/BF00666006. [DOI] [PubMed] [Google Scholar]
  39. Yu H., Giai M., Diamandis E. P., Katsaros D., Sutherland D. J., Levesque M. A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15;55(10):2104–2110. [PubMed] [Google Scholar]
  40. Yu H., Levesque M. A., Clark G. M., Diamandis E. P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res. 1998 Jun;4(6):1489–1497. [PubMed] [Google Scholar]
  41. Zarghami N., Grass L., Diamandis E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75(4):579–588. doi: 10.1038/bjc.1997.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. de Witte H. H., Foekens J. A., Lennerstrand J., Smid M., Look M. P., Klijn J. G., Benraad T. J., Berns E. M. Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer. 1996 Apr 22;69(2):125–130. doi: 10.1002/(SICI)1097-0215(19960422)69:2<125::AID-IJC10>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES